STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Armistice Capital and Steven Boyd Report 1.27M Shares of MetaVia

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

MetaVia Inc. Reporting persons Armistice Capital, LLC and Steven Boyd disclose beneficial ownership of 1,270,887 shares of MetaVia common stock, representing 4.99% of the class. Armistice Capital is the investment manager to Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares reported. Mr. Boyd, as managing member of Armistice Capital, is also reported as having shared voting and dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Positive

  • Transparent disclosure of beneficial ownership and allocation of voting/dispositive power
  • Position below 5% indicates no presumption of intent to influence control under reporting rules
  • Certification that shares are held in the ordinary course of business and not to change control

Negative

  • Shared voting/dispositive power centralizes authority in Armistice Capital and its managing member
  • Concentration of 4.99% is material enough to be notable but just below thresholds that require different reporting or could signal activist intent

Insights

TL;DR: Armistice reports a sub-5% stake with shared voting/dispositive power through its managed fund, a routine disclosure without control intent.

This Schedule 13G/A clarifies that Armistice Capital, via its master fund, holds 1,270,887 shares or 4.99% of MetaVia's common stock and that voting and disposition powers are shared rather than sole. The filing emphasizes the ordinary-course nature of the holdings and disclaims an intent to influence control. For investors, this signals institutional interest below the 5% threshold that would typically trigger more stringent reporting or presumptions of activist intent.

TL;DR: Disclosure is standard: investment manager and managing member report beneficial ownership and assert ordinary-course purpose; no governance change indicated.

The document delineates the relationships between the Master Fund, Armistice Capital, and Steven Boyd, assigning shared voting and dispositive power to the reporting persons. The Master Fund disclaims direct beneficial ownership due to its investment management agreement. The certification asserts the position is not meant to change control, which reduces immediate governance risk for the issuer. The structure, however, concentrates decision authority in the investment manager and its managing member for the reported stake.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025

FAQ

What stake in MetaVia Inc. is reported by Armistice Capital and Steven Boyd?

The filing reports beneficial ownership of 1,270,887 shares, equal to 4.99% of MetaVia's common stock.

Who holds voting and dispositive power over the shares?

The filing states shared voting power and shared dispositive power of 1,270,887 shares are held by Armistice Capital and Steven Boyd.

Does the filing indicate an intent to influence control of the issuer?

No. The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control.

What is the relationship between Armistice Capital and the direct holder of the shares?

Armistice Capital is the investment manager to Armistice Capital Master Fund Ltd., which is the direct holder of the reported shares; the manager exercises voting and investment power under an Investment Management Agreement.

When was the Schedule 13G/A signed?

The document shows signatures dated 08/14/2025.
Neurobo Pharmaceuticals Inc

NASDAQ:NRBO

NRBO Rankings

NRBO Latest News

NRBO Latest SEC Filings

NRBO Stock Data

20.33M
3.00M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
US
CAMBRIDGE